Cargando…

Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests

We show through a simulation study how the joint analysis of data from phase I and phase II studies enhances the power of pharmacogenetic tests in pharmacokinetic (PK) studies. PK profiles were simulated under different designs along with 176 genetic markers. The null scenarios assumed no genetic ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tessier, A, Bertrand, J, Chenel, M, Comets, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807465/ https://www.ncbi.nlm.nih.gov/pubmed/27069775 http://dx.doi.org/10.1002/psp4.12054

Ejemplares similares

Phase I and Phase II CMS upgrade
por: Heister, A
Publicado: (2014)

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours
por: Soo, Ross Andrew, et al.
Publicado: (2016)

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
por: Anthoney, D Alan, et al.
Publicado: (2012)

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis
por: Kim, Sun Young, et al.
Publicado: (2017)

Experimental designs for phase I and phase I/II dose-finding studies
por: O'quigley, J, et al.
Publicado: (2006)

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
por: Bota, Daniela A, et al.
Publicado: (2021)

Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway
por: He, Ming-ming, et al.
Publicado: (2016)

Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk
por: Justenhoven, Christina
Publicado: (2012)

Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials
por: Yada, Shinjo, et al.
Publicado: (2017)

S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis
por: Kim, S Y, et al.
Publicado: (2013)

Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
por: Ursino, Moreno, et al.
Publicado: (2017)

Using phase II data for the analysis of phase III studies: An application in rare diseases
por: Wandel, Simon, et al.
Publicado: (2017)

Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings
por: Smith, D. Max, et al.
Publicado: (2020)

Design of the CMS upgraded trigger from Phase I to Phase II of the LHC
por: Donato, Silvio
Publicado: (2018)

Design of the CMS upgraded trigger from Phase I to Phase II of the LHC
por: Jeitler, Manfred
Publicado: (2019)

R&D results of iRPC tested at GIF++ for the CMS Phase-II upgrade
por: Lim, Jae Hoon
Publicado: (2018)

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
por: Inokuchi, M, et al.
Publicado: (2006)

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
por: Koizumi, W, et al.
Publicado: (2003)

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies
por: Ahn, Jae Eun, et al.
Publicado: (2023)

Optimizing the data combination rule for seamless phase II/III clinical trials
por: Hampson, Lisa V, et al.
Publicado: (2015)

The Potential Utility of Pharmacogenetic Testing in Psychiatry
por: Gardner, Kathryn R., et al.
Publicado: (2014)

Variant Interpretation in Current Pharmacogenetic Testing
por: Luvsantseren, Sally, et al.
Publicado: (2020)

The Utility of Pharmacogenetics Testing in Psychiatric Populations
por: Jürgens, Gesche
Publicado: (2021)

EXPERIENCE OF PHARMACOGENETIC TESTING IN THE TREATMENT OF ANTIPSYCHOTICS
por: Kaydan, M., et al.
Publicado: (2023)

Design of the CMS calorimeter trigger upgrade from Phase I to Phase II of the LHC
por: Zabi, Alexandre
Publicado: (2018)

OSAS Surgery and Postoperative Discomfort: Phase I Surgery versus Phase II Surgery
por: Gasparini, Giulio, et al.
Publicado: (2015)

Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development
por: Lee, Daniel Y., et al.
Publicado: (2019)

Design, power, and alpha levels in randomized phase II oncology trials
por: Haslam, A., et al.
Publicado: (2023)

Trick or treat: The effect of placebo on the power of pharmacogenetic association studies
por: Singer, Clara, et al.
Publicado: (2005)

Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs
por: Burgueño-Rodríguez, Gabriela, et al.
Publicado: (2023)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Estrogenic in vitro evaluation of zearalenone and its phase I and II metabolites in combination with soy isoflavones
por: Grgic, Dino, et al.
Publicado: (2022)

Enhanced phase-locked loop structures for power and energy applications
por: Karimi-Ghartema, Masoud
Publicado: (2014)

Pharmacogenetic testing in the Veterans Health Administration: Policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee
por: Vassy, Jason L., et al.
Publicado: (2018)

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy
por: Nurgat, Z A, et al.
Publicado: (2005)

Synthesis of Human Phase I and Phase II Metabolites of Hop (Humulus lupulus) Prenylated Flavonoids
por: Buckett, Lance, et al.
Publicado: (2022)

Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions
por: Böhm, Ruwen, et al.
Publicado: (2016)

Positive perception of pharmacogenetic testing for psychotropic medications
por: Lanktree, Matthew B, et al.
Publicado: (2014)

Pharmacogenetic testing in oncology: a Brazilian perspective
por: Suarez-Kurtz, Guilherme
Publicado: (2018)

Physicians’ Attitudes and Ethical Obligations to Pharmacogenetic Testing
por: Muflih, Suhaib, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n9o7vnb93oaqpeiuiaa8g315kh